Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Annamycin liposomal - Moleculin Biotech

Drug Profile

Annamycin liposomal - Moleculin Biotech

Alternative Names: Annamycin-LF; Annamycin-liposomal; L-ANNA; L-annamycin; Liposomal annamycin; S-ANNA

Latest Information Update: 16 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Aronex Pharmaceuticals; Callisto Pharmaceuticals; Moleculin Biotech; University of Texas M. D. Anderson Cancer Center
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma; Acute myeloid leukaemia; Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Soft tissue sarcoma
  • Phase I/II Acute myeloid leukaemia
  • Preclinical Colorectal cancer; Liver cancer; Pancreatic cancer; Solid tumours
  • Discontinued Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Triple negative breast cancer

Most Recent Events

  • 09 May 2024 Moleculin Biotech receives patent issue notification for Annamycin from USPTO
  • 09 May 2024 Moleculin Biotech plans a pivotal trial (MB-108) for Acute myeloid leukaemia (Second-line therapy or greater) in 2024
  • 07 May 2024 Moleculin Biotech announces intention to submit NDA to US FDA for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in 2027
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top